Phase 1 Radioimmunotherapy Study with Lutetium 177–labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma

Stillebroer, Alexander B.; Boerman, Otto C.; Desar, Ingrid M.E.; Boers-Sonderen, Marije J.; Herpen, Carla M.L. van; Langenhuijsen, J.F.; Smith‐Jones, Peter; Oosterwijk, Egbert; Oyen, Wim J.G.; Mulders, Peter F.A.

doi:10.1016/j.eururo.2012.08.024

Cited by 72 publications

(75 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because of its long half-life (59.4 d) and less favorable g characteristics (g energy 5 35 keV), 125 I is not suitable for SPECT imaging in the clinical setting. Labeling of girentuximab-IRDye800CW with 124 I or with the residualizing radiometal 111 In by use of the chelator DTPA could enable preoperative molecular imaging in patients with ccRCC tumors and thus enable both pre-and perioperative imaging of ccRCC tumors (24)(25)(26)(27). Recently, Divgi et al (26) assessed the accuracy of 124 I-girentuximab PET/CT in a large cohort of patients with a primary renal mass scheduled for surgery.…”

Section: Discussionmentioning

confidence: 99%

Optical Imaging of Renal Cell Carcinoma with Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab

et al. 2014

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Optical Imaging of Renal Cell Carcinoma with Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab

et al. 2014

Self Cite

View full text Add to dashboard Cite

“…In the setting of metastatic disease, 124 I-girentuximab PET has been shown to identify anatomically occult regional node metastasis [44]. Furthermore, conventional scintigraphy showed high and specific uptake of 111 In-cG250 in metastatic lesions, including lung lesions, considered difficult to visualize with 131 I-cG250 [45]. The advantage of PET over conventional scintigraphy is the higher spatial resolution and the ability to accurately determine antibody uptake in tissues [46].…”

Section: Novel Imaging Modalitiesmentioning

confidence: 99%

Post Partial Nephrectomy Surveillance Imaging: an Evidence-Based Approach

Gorin

Allaf

2015

Curr Urol Rep

View full text Add to dashboard Cite

To ensure the early detection of recurrent disease, all patients should undergo routine surveillance following partial nephrectomy for renal cell carcinoma. In order to optimize resource allocation and avoid unnecessary radiation exposure, the frequency and duration of surveillance should be tailored to the individual patient's risk of cancer recurrence. The evidence for surveillance after partial nephrectomy is presented reviewing the current literature on prognostic models and proposed surveillance protocols based on the timing and patterns of renal cell carcinoma recurrence. In addition, we review recent guidelines on post partial nephrectomy surveillance as well as the literature on novel imaging techniques that may aid in early disease discovery.

show abstract

“…[123,124] In a phase III trial with Rencarex to treat ccRCC, Rencarex treatment did not improve median disease-free survival compared with placebo; however, further subgroup analysis revealed that the Rencarex effect became more pronounced for higher CAIX scores (http://www.wilex.de/ portfolio-english/rencarex/phase-iii-ariser/#Status, accessed June 2015). A phase I radioimmunotherapy study with 177 Lu-labeled girentuximab showed that the drug is well tolerated in metastatic ccRCC patients [125]; this was followed by a phase II study in patients with advanced renal cancer (clinicaltrials.gov identifier: NCT02002312). Radiolabeled girentuximab is valued in the presurgical diagnosis and characterization of ccRCC patients.…”

Section: Therapeutic Agents Targeting Hypoxiamentioning

confidence: 99%

Targeting Tumor Hypoxia in Radiotherapy: A Brief Review of Historical Background and Recent Progress

Zhang¹,

Zhou²,

Zhao³

et al. 2016

ERHM

View full text Add to dashboard Cite

Tumor hypoxia is a physiologic barrier to radiotherapy and anti-tumor drug delivery. Numerous efforts have been made to overcome this barrier and to improve therapeutic outcomes. Strategies for targeting tumor hypoxia have included chemical radiosensitizers and hyperthermia, followed by combined synergic therapeutic modalities. Clinical hypoxia measurements and the development of molecular imaging agents prompted trials on dose escalation in external beam radiotherapy, which takes advantage of contemporary sophisticated radiation dose delivery techniques. Increases in our understanding of hypoxia-induced biological pathways have led to the investigation of various hypoxia targeting drugs. Radiolabeled hypoxia targeting drugs deliver radionuclides into hypoxic tumor cells and achieve highly localized cell death. In this manuscript, we briefly review the methods of targeting tumor hypoxia in radiotherapy. These include image guided dose escalation in external beam radiotherapy, radiosensitizers, and radiolabeled agents targeting hypoxia pathways and the receptors on hypoxic tumor cells. Our current understanding of tumor hypoxia is the culmination of the collective efforts of generations of researchers. New frontiers are continuing to expand, as new discoveries are being made on both the macroscopic and molecular levels.

show abstract

Phase 1 Radioimmunotherapy Study with Lutetium 177–labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma

Cited by 72 publications

References 21 publications

Optical Imaging of Renal Cell Carcinoma with Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab

Optical Imaging of Renal Cell Carcinoma with Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab

Post Partial Nephrectomy Surveillance Imaging: an Evidence-Based Approach

Targeting Tumor Hypoxia in Radiotherapy: A Brief Review of Historical Background and Recent Progress

Contact Info

Product

Resources

About